Evaluation of the Clinical Characteristics, Real-world Treatment Pathways, and Outcomes of Patients With Moderate Rheumatoid Arthritis.
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2013
At a glance
- Drugs Etanercept (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 19 Dec 2012 Planned end date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov record.
- 26 Mar 2012 New trial record